SPOTLIGHT -
What happened in optometry this week: April 1 - April 5
Catch up on what happened in optometry during the week of April 1-April 5.
New near VA card facilitates accurate self-monitoring of vision by patients
The Hadassah Self-Visual Acuity Screener (HSVA) has high test–retest reliability, accuracy, and alignment with clinical-standard VA tests, according to a study conducted by its developers.
Manuscript outlines increased risk of diabetic eye disease in Black Alabamians, encourages community collaboration
The manuscript, "Breaking Barriers: Partnerships to Improve Diabetic Eye Health in Alabama," highlights the burden of diabetic eye disease in Alabama, as well as strategies that target racial health disparities within that population.
Qlaris Bio announces initiation for 2 Phase 2 trials of QLS-111 for lowering IOP
The trials will include patients with ocular hypertension, and assess QLS-111 in its efficacy for lowering IOP beyond levels currently achievable by targeting EVP.
Don't look at the sun: Keeping eyes safe during the total solar eclipse
Jill Saxon, OD, FAAO, chats about eye health safety for the upcoming total solar eclipse on April 8, 2024, and how Bausch + Lomb is celebrating the celestial event.
Researchers use viscous seaweed to treat retinal detachment
The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.
Meibomian gland dysfunction: At-home treatment devices
Warm compresses are an invaluable step in the treatment of dry eye.
ViaLase announces closure of financing series with $40 million for laser advancement
The clinical stage medical technology company is developing a laser system that performs femtosecond laser image-guided high-precision trabeculomtomy, or FLigHT.
Neurolens's impactful role in headache reduction with CEO Davis Corley
Davis Corley, CEO of Neurolens, outlines the importance a new study that show statistically significant improvement of headaches with the use of Neurolens.
Phentolamine 0.75% launches commercially in the US
Phentolamine ophthalmic solution 0.75% is a preservative-free, stable eye drop, which blocks the α1 receptor within the iris dilator muscle without affecting the ciliary muscle.
How those with low vision, blindness can utilize the ARx AI headset
Charles Leclercq, CEO of ARxVision, outlines the conception of ARxVIsion's collaboration with Seeing AI and NaviLens apps, and details the popular uses for the headset so far.
What happened in optometry this week: March 25 - March 29
Catch up on what happened in optometry during the week of March 25-March 29.
LENZ Therapeutics anticipating NDA submission for LNZ100 or LNZ101 eye drops
The company, which has completed each of its CLARITY trials for both eye drops, will be reporting on their findings next month.
Secondary analysis suggests DED severity, systemic medication use correlation
The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.
ARxVision, Seeing AI, NaviLens team up for pilot headset program
The ARx Gen 1.5 wearable headset will be integrating the 2 apps in part of a pilot program providing a hands-free visual assistant service.
Study finds high risk of myopic maculopathy in population over 85 years old
The Russian study also found that the aging of a young myopic generation may result in even more visual impairment and blindness as the result of myopic macular degeneration.
First Canadian participant dosed in Phase 1/2 ABA-1, CLARA clinical trial of AURN001
The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
Nanoscope Therapeutics lead candidate MCO-010 meets endpoints in RESTORE trial for retinitis pigmentosa
MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.
You and Eye: On contact lenses, personalization, and boosting optical sales
One of the 15 clinics Miriam Korik, OD, works at is an optical boutique. She shares her expertise on exam personalization and how to realize these tweaks as sales.
Astellas receives permanent J-code for avacincaptad pegol intravitreal solution for GA
Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.